Keywords: ppis, lead, growth, 5b, otc, gastro, market
PPIs lead growth in $2.5B US OTC gastro market
Article | 23 August 2004
US sales of over-the-counter gastrointestinal drugs approached $2.5billion in 2003, helped by the newly-switched proton pump inhibitors, says a new study ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
